Product Description
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Belgium | Germany | Italy | Jordan | Korea | Mexico | Morocco | Poland | Portugal | Turkey
Approved Indications: None
Known Adverse Events: None
Company: Università degli Studi di Brescia
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Macular Edema|Cataract
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2300073199 |
ChiCTR2300073199 | N/A |
Not yet recruiting |
Keratoconjunctivitis Sicca |
2023-08-30 |
2023-07-04 |
Treatments |
|
ChiCTR2100047726 |
ChiCTR2100047726 | N/A |
Completed |
Pterygium |
2020-12-31 |
|||
ChiCTR1900021312 |
ChiCTR1900021312 | N/A |
Recruiting |
Cataract |
2019-01-31 |
|||
NCT03013959 |
OHSV | N/A |
Unknown status |
Keratitis, Herpetic|Herpes Simplex |
2018-03-01 |
2019-03-21 |
Treatments |
|
NCT03712670 |
Oral001 | N/A |
Completed |
Macular Degeneration |
2016-12-31 |
2019-03-22 |
Treatments |
|
ChiCTR-IPR-15007196 |
ChiCTR-IPR-15007196 | N/A |
Recruiting |
Keratoconjunctivitis Sicca |
2016-03-31 |
|||
NCT07291089 |
CCTR-2023C03-R | P4 |
Completed |
Cataract |
2025-11-20 |
2026-02-25 |
Primary Endpoints|Treatments|Trial Status |
|
NCT03355638 |
NSAIDs_03 | P4 |
Completed |
Macular Edema |
2016-07-01 |
2019-03-21 |
Treatments |